Patient and transplant characteristics
| . | Ph-like fusions (N = 56) . | Others (N = 71) . | Total (N = 127) . | P . |
|---|---|---|---|---|
| Age at HSCT, y | .12 | |||
| Median (range) | 35 (19-70) | 40 (18-72) | 39 (18-72) | |
| Recipient sex (%) | .70 | |||
| Male | 35 (62.5) | 42 (59.2) | 77 (60.6) | |
| Female | 21 (37.5) | 29 (40.8) | 50 (39.4) | |
| Race (%) | .008 | |||
| White | 6 (10.7) | 24 (33.8) | 30 (23.6) | |
| Hispanic | 46 (82.1) | 44 (62) | 90 (70.9) | |
| Asian | 3 (5.4) | 2 (2.8) | 5 (3.9) | |
| African American | 1 (1.8) | 1 (1.4) | 2 (1.6) | |
| Cytogenetics (%) | <.001 | |||
| Good/intermediate | 53 (94.6) | 45 (63.4) | 98 (77.2) | |
| High | 3 (5.4) | 26 (36.6) | 29 (22.8) | |
| KMT2A (MLL) translocation | 0 | 9 (35) | 9 (31) | |
| Hypodiploidy | 0 | 8 (30.5) | 8 (28) | |
| Complex (≥5 abnormalities) | 3 (100) | 8 (30.5) | 11 (38) | |
| T(17;19) | 0 | 1 (4) | 1 (3) | |
| WBC at diagnosis | .45 | |||
| Median (range) | 21.8 (0.6-512.0) | 13.4 (0.3-560.0) | 19.2 (0.3-560.0) | |
| Time from diagnosis to HCT, mo | .22 | |||
| Median (range) | 8.6 (2.7-50.2) | 6.1 (2.9-239.6) | 6.8 (2.7-239.6) | |
| Disease status at HCT (%) | .89 | |||
| CR1 | 34 (60.7) | 44 (62) | 78 (61.4) | |
| CR2/3 | 22 (39.3) | 27 (38) | 49 (38.6) | |
| MRD status at HCT (%) | .12 | |||
| Negative | 35 (79.5) | 41 (91.1) | 76 (59.8) | |
| Positive | 9 (20.5) | 4 (8.9) | 13 (10.2) | |
| Unknown | 12 | 26 | 38 (29.9) | |
| Prior blinatumomab (%) | .019 | |||
| No | 23 (41.1) | 44 (62) | 67 (52.8) | |
| Yes | 33 (58.9) | 27 (38) | 60 (47.2) | |
| Prior inotuzumab (%) | .42 | |||
| No | 46 (82.1) | 62 (87.3) | 108 (85) | |
| Yes | 10 (17.9) | 9 (12.7) | 19 (15) | |
| Donor (%) | .86 | |||
| Match sibling | 16 (28.6) | 25 (35.2) | 41 (32.3) | |
| Match unrelated | 16 (28.6) | 21 (29.6) | 37 (29.1) | |
| Mismatched unrelated | 9 (16.1) | 8 (11.3) | 17 (13.4) | |
| Haplo-identical | 14 (25) | 15 (21.1) | 29 (22.8) | |
| Cord blood | 1 (1.8) | 2 (2.8) | 3 (2.4) | |
| Conditioning regimen (%) | .89 | |||
| Myeloablative | 38 (67.9) | 49 (69) | 87 (68.5) | |
| Reduce intensity/nonmyeloablative | 18 (32.1) | 22 (31) | 40 (31.5) | |
| Stem cell l source (%) | .44 | |||
| Peripheral blood stem cells | 55 (98.2) | 66 (93) | 121 (95.3) | |
| Bone marrow | 0 (0) | 3 (4.2) | 3 (2.4) | |
| Cord blood | 1 (1.8) | 2 (2.8) | 3 (2.4) | |
| GVHD prophylaxis (%) | .64 | |||
| Tacrolimus/sirolimus-based | 31 (55.4) | 43 (60.6) | 74 (58.3) | |
| PTCy/tacrolimus/MMF-based | 20 (35.7) | 20 (28.2) | 40 (31.5) | |
| Others | 5 (8.9) | 8 (11.3) | 13 (10.2) | |
| Induction regimen (%) | .15 | |||
| Hyper-CVAD | 15 (26.8) | 32 (45.1) | 47 (37) | |
| Pediatric inspired | 23 (41.1) | 19 (26.8) | 42 (33.1) | |
| COG/CCG | 9 (16.1) | 8 (11.3) | 17 (13.4) | |
| Others | 9 (16.1) | 12 (16.9) | 21 (16.5) | |
| Number of therapies for CR1 (%) | .009 | |||
| 1 | 14 (41.2) | 31 (70.5) | 45 (57.7) | |
| ≥2 | 20 (58.8) | 13 (29.5) | 33 (42.3) | |
| Karnofsky performance status (%) | .53 | |||
| 90-100 | 34 (60.7) | 37 (52.1) | 71 (55.9) | |
| 70-80 | 17 (30.4) | 26 (36.6) | 43 (33.9) | |
| 40-60 | 2 (3.6) | 1 (1.4) | 3 (2.4) | |
| Unknown | 3 (5.4) | 7 (9.9) | 10 (7.9) | |
| HCT comorbidity index (%) | .095 | |||
| 0 | 8 (14.3) | 16 (22.5) | 24 (18.9) | |
| 1-2 | 27 (48.2) | 19 (26.8) | 46 (36.2) | |
| ≥3 | 18 (32.1) | 30 (42.3) | 48 (37.8) | |
| Unknown | 3 (5.4) | 6 (8.5) | 9 (7.1) | |
| HCT year (%) | .15 | |||
| 2006-2014 | 11 (19.6) | 22 (31) | 33 (26) | |
| 2015-2020 | 45 (80.4) | 49 (69) | 94 (74) |
| . | Ph-like fusions (N = 56) . | Others (N = 71) . | Total (N = 127) . | P . |
|---|---|---|---|---|
| Age at HSCT, y | .12 | |||
| Median (range) | 35 (19-70) | 40 (18-72) | 39 (18-72) | |
| Recipient sex (%) | .70 | |||
| Male | 35 (62.5) | 42 (59.2) | 77 (60.6) | |
| Female | 21 (37.5) | 29 (40.8) | 50 (39.4) | |
| Race (%) | .008 | |||
| White | 6 (10.7) | 24 (33.8) | 30 (23.6) | |
| Hispanic | 46 (82.1) | 44 (62) | 90 (70.9) | |
| Asian | 3 (5.4) | 2 (2.8) | 5 (3.9) | |
| African American | 1 (1.8) | 1 (1.4) | 2 (1.6) | |
| Cytogenetics (%) | <.001 | |||
| Good/intermediate | 53 (94.6) | 45 (63.4) | 98 (77.2) | |
| High | 3 (5.4) | 26 (36.6) | 29 (22.8) | |
| KMT2A (MLL) translocation | 0 | 9 (35) | 9 (31) | |
| Hypodiploidy | 0 | 8 (30.5) | 8 (28) | |
| Complex (≥5 abnormalities) | 3 (100) | 8 (30.5) | 11 (38) | |
| T(17;19) | 0 | 1 (4) | 1 (3) | |
| WBC at diagnosis | .45 | |||
| Median (range) | 21.8 (0.6-512.0) | 13.4 (0.3-560.0) | 19.2 (0.3-560.0) | |
| Time from diagnosis to HCT, mo | .22 | |||
| Median (range) | 8.6 (2.7-50.2) | 6.1 (2.9-239.6) | 6.8 (2.7-239.6) | |
| Disease status at HCT (%) | .89 | |||
| CR1 | 34 (60.7) | 44 (62) | 78 (61.4) | |
| CR2/3 | 22 (39.3) | 27 (38) | 49 (38.6) | |
| MRD status at HCT (%) | .12 | |||
| Negative | 35 (79.5) | 41 (91.1) | 76 (59.8) | |
| Positive | 9 (20.5) | 4 (8.9) | 13 (10.2) | |
| Unknown | 12 | 26 | 38 (29.9) | |
| Prior blinatumomab (%) | .019 | |||
| No | 23 (41.1) | 44 (62) | 67 (52.8) | |
| Yes | 33 (58.9) | 27 (38) | 60 (47.2) | |
| Prior inotuzumab (%) | .42 | |||
| No | 46 (82.1) | 62 (87.3) | 108 (85) | |
| Yes | 10 (17.9) | 9 (12.7) | 19 (15) | |
| Donor (%) | .86 | |||
| Match sibling | 16 (28.6) | 25 (35.2) | 41 (32.3) | |
| Match unrelated | 16 (28.6) | 21 (29.6) | 37 (29.1) | |
| Mismatched unrelated | 9 (16.1) | 8 (11.3) | 17 (13.4) | |
| Haplo-identical | 14 (25) | 15 (21.1) | 29 (22.8) | |
| Cord blood | 1 (1.8) | 2 (2.8) | 3 (2.4) | |
| Conditioning regimen (%) | .89 | |||
| Myeloablative | 38 (67.9) | 49 (69) | 87 (68.5) | |
| Reduce intensity/nonmyeloablative | 18 (32.1) | 22 (31) | 40 (31.5) | |
| Stem cell l source (%) | .44 | |||
| Peripheral blood stem cells | 55 (98.2) | 66 (93) | 121 (95.3) | |
| Bone marrow | 0 (0) | 3 (4.2) | 3 (2.4) | |
| Cord blood | 1 (1.8) | 2 (2.8) | 3 (2.4) | |
| GVHD prophylaxis (%) | .64 | |||
| Tacrolimus/sirolimus-based | 31 (55.4) | 43 (60.6) | 74 (58.3) | |
| PTCy/tacrolimus/MMF-based | 20 (35.7) | 20 (28.2) | 40 (31.5) | |
| Others | 5 (8.9) | 8 (11.3) | 13 (10.2) | |
| Induction regimen (%) | .15 | |||
| Hyper-CVAD | 15 (26.8) | 32 (45.1) | 47 (37) | |
| Pediatric inspired | 23 (41.1) | 19 (26.8) | 42 (33.1) | |
| COG/CCG | 9 (16.1) | 8 (11.3) | 17 (13.4) | |
| Others | 9 (16.1) | 12 (16.9) | 21 (16.5) | |
| Number of therapies for CR1 (%) | .009 | |||
| 1 | 14 (41.2) | 31 (70.5) | 45 (57.7) | |
| ≥2 | 20 (58.8) | 13 (29.5) | 33 (42.3) | |
| Karnofsky performance status (%) | .53 | |||
| 90-100 | 34 (60.7) | 37 (52.1) | 71 (55.9) | |
| 70-80 | 17 (30.4) | 26 (36.6) | 43 (33.9) | |
| 40-60 | 2 (3.6) | 1 (1.4) | 3 (2.4) | |
| Unknown | 3 (5.4) | 7 (9.9) | 10 (7.9) | |
| HCT comorbidity index (%) | .095 | |||
| 0 | 8 (14.3) | 16 (22.5) | 24 (18.9) | |
| 1-2 | 27 (48.2) | 19 (26.8) | 46 (36.2) | |
| ≥3 | 18 (32.1) | 30 (42.3) | 48 (37.8) | |
| Unknown | 3 (5.4) | 6 (8.5) | 9 (7.1) | |
| HCT year (%) | .15 | |||
| 2006-2014 | 11 (19.6) | 22 (31) | 33 (26) | |
| 2015-2020 | 45 (80.4) | 49 (69) | 94 (74) |